中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(9): 2009-2015

A methodological study of traditional Chinese medicine treatment of primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2021.09.003

  • Department of Hepatology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China

  • Received Date: 2021-04-08
  • Accepted Date: 2021-04-08
  • Published Date: 2021-09-20
    Abstract
  • With in-depth studies on the etiology and pathogenesis, pathological viscera and bowels, and rule of disease progression of primary liver cancer in recent years, some clinical and experimental results have been achieved for the treatment of primary liver cancer with traditional Chinese medicine, such as treatment based on syndrome differentiation and disease differentiation, compound prescriptions and monomers of Chinese herbs, oral administration of drugs/acupuncture and moxibustion/external application, and prevention before disease onset and prevention of recurrence, which reflects the rich methodological connotations of traditional Chinese medicine and lays a foundation for constructing a new diagnostic and therapeutic mode for liver cancer based on integrated traditional Chinese and Western medicine therapy.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention for primary liver cancer (2021 edition)[J]. J Clin Hepatol, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.

    中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.
    [2]
    Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [3]
    YIN CJ. Several theoretical and practical issues in traditional Chinese medicine treatment of liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29(2): 112-113, 117. DOI: 10.3969/j.issn.1005-0264.2019.02.005.

    尹常健. 中医药治疗肝癌的几个理论与实践问题[J]. 中西医结合肝病杂志, 2019, 29(2): 112-113, 117. DOI: 10.3969/j.issn.1005-0264.2019.02.005.
    [4]
    LI WZ, REN MM, WEI XM, et al. Analysis on differentiation and treatment of liver cancer based on cancer-toxin pathogenesis theory[J]. J Oncol Chin Med, 2020, 2(1): 20-23. DOI: 10.19811/j.cnki.issn.2096-6628.2020.01.005.

    李维忠, 任明名, 魏小曼, 等. 癌毒病机理论辨治肝癌探析[J]. 中医肿瘤学杂志, 2020, 2(1): 20-23. DOI: 10.19811/j.cnki.issn.2096-6628.2020.01.005.
    [5]
    JIAN HY, ZENG PH, GAO WH. Discussion on transmission of cancer toxin of primary liver cancer from perspective of liver, spleen and kidney[J]. J New Chin Med, 2021, 53(3): 125-128. DOI: 10.13457/j.cnki.jncm.2021.03.032.

    翦慧颖, 曾普华, 郜文辉. 从肝脾肾相关探讨原发性肝癌之癌毒传变[J]. 新中医, 2021, 53(3): 125-128. DOI: 10.13457/j.cnki.jncm.2021.03.032.
    [6]
    YIN CJ. Ten lectures on medication for liver diseases[M]. Beijing: China Press of Traditional Chinese Medicine, 2007: 312-316.

    尹常健. 肝病用药十讲[M]. 北京: 中国中医药出版社, 2007: 312-316.
    [7]
    ZHANG N, LI HJ. Qi Yuanfu's experience in treating liver cancer[J]. Henan Tradit Chin Med, 2013, 33(10): 1688-1689. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY201310048.htm

    张暖, 李慧杰. 齐元富治疗肝癌经验[J]. 河南中医, 2013, 33(10): 1688-1689. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZY201310048.htm
    [8]
    WANG XT, CHEN XJ. Chen Xinju's clinical experience in the treatment of liver cancer[J]. Forum Tradit Chin Med, 2020, 35(6): 48-50. https://www.cnki.com.cn/Article/CJFDTOTAL-GYLT202006022.htm

    王新亭, 陈欣菊. 陈欣菊治疗肝癌的临床经验[J]. 国医论坛, 2020, 35(6): 48-50. https://www.cnki.com.cn/Article/CJFDTOTAL-GYLT202006022.htm
    [9]
    FAN BF, HOU L, JIA LQ, et al. Expert consensus on rational use of Chinese patent drugs in standardized treatment of cancer pain[J]. Chin J Pain Med, 2021, 27(1): 9-17. DOI: 10.3969/j.issn.1006-9852.2021.01.003.

    樊碧发, 侯丽, 贾立群, 等. 癌痛规范化治疗中成药合理使用专家共识[J]. 中国疼痛医学杂志, 2021, 27(1): 9-17. DOI: 10.3969/j.issn.1006-9852.2021.01.003.
    [10]
    YAN JT, LI ZS, FAN HY. Policies for treating cancer fever in TCM[J]. Clin J Chin Med, 2016, 8(4): 47-49. DOI: 10.3969/j.issn.1674-7860.2016.04.023.

    闫京涛, 李竹生, 范宏宇. 中医药治疗癌性发热的思路与方法[J]. 中医临床研究, 2016, 8(4): 47-49. DOI: 10.3969/j.issn.1674-7860.2016.04.023.
    [11]
    ZENG W, LIU H, SUN TL, et al. Clinical effect of modified Danggui Liuhuang decoction in treatment of cancerous fever in patients with advanced tumor: An analysis of 30 cases[J]. Hunan J Tradit Chin Med, 2020, 36(10): 39-41. DOI: 10.16808/j.cnki.issn.1003-7705.2020.10.016.

    曾万, 刘华, 孙铜林, 等. 当归六黄汤加减治疗晚期肿瘤癌性发热30例临床观察[J]. 湖南中医杂志, 2020, 36(10): 39-41. DOI: 10.16808/j.cnki.issn.1003-7705.2020.10.016.
    [12]
    WEN B, JIANG JP. Clinical effect of modified Qinggu powder in treatment of cancerous fever[J/CD]. J Clin Med Literature (Electronic Edition), 2018, 5(52): 65-66. DOI: 10.3877/j.issn.2095-8242.2018.52.033.

    闻彬, 蒋霁鹏. 清骨散加减治疗癌性发热的疗效观察[J/CD]. 临床医药文献电子杂志, 2018, 5(52): 65-66. DOI: 10.3877/j.issn.2095-8242.2018.52.033.
    [13]
    PANG B, JIANG XC, LIN BK, et al. Clinical thinking methods in disease differentiation-based treatment of tumor[J]. Beijing J Tradit Chin Med, 2020, 39(5): 397-401. DOI: 10.16025/j.1674-1307.2020.05.001.

    庞博, 姜晓晨, 朴炳奎, 等. 肿瘤辨病论治临床思维方法探讨[J]. 北京中医药, 2020, 39(5): 397-401. DOI: 10.16025/j.1674-1307.2020.05.001.
    [14]
    YANG GB, LIU SL, LIU YF, et al. Discussion on the application of the thought of combined treatment of miscellaneous diseases in the diagnosis and treatment of primary liver cancer[J]. J Hubei Univ Chin Med, 2020, 22(2): 55-59. DOI: 10.3969/j.issn.1008-987x.2020.02.14.

    阳国彬, 刘松林, 刘玉芳, 等. 《金匮要略》杂病脉证并治思想在原发性肝癌辨治中的应用探析[J]. 湖北中医药大学学报, 2020, 22(2): 55-59. DOI: 10.3969/j.issn.1008-987x.2020.02.14.
    [15]
    LI LX, DAI Q, CHEN KS. Chen Kunshan's experience in treating malignant tumors[J]. Hubei J Tradit Chin Med, 2020, 42(6): 23-25. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZZ202006008.htm

    李凌霄, 戴琦, 陈崑山. 陈崑山治疗恶性肿瘤临证经验[J]. 湖北中医杂志, 2020, 42(6): 23-25. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZZ202006008.htm
    [16]
    HUANG FX, WANG Y, HUANG MH. Discussion on treatment thoughts for cancers based on theory of warming yang and strengthening vital energy[J]. Chin J Inf Tradit Chin Med, 2020, 27(11): 125-127. DOI: 10.19879/j.cnki.1005-5304.201904392.

    黄飞霞, 王银, 黄明河. 从温阳扶正论治癌症思路探讨[J]. 中国中医药信息杂志, 2020, 27(11): 125-127. DOI: 10.19879/j.cnki.1005-5304.201904392.
    [17]
    WANG J, XU JL, DU YH. Effect of Fuzheng Quxie decoction on intestinal microflora microecological environment of liver cancer model rats[J]. Shaanxi J Tradit Chin Med, 2021, 42(2): 143-147. DOI: 10.3969/j.issn.1000-7369.2021.02.002.

    王军, 徐建良, 杜燕红. 扶正祛邪汤对肝癌模型大鼠肠道菌群微生态环境的作用研究[J]. 陕西中医, 2021, 42(2): 143-147. DOI: 10.3969/j.issn.1000-7369.2021.02.002.
    [18]
    CHENG Y, NI SS, CHEN JJ. Prof. Jianjie Chen's experience in treating liver cancer after surgery with syndrome differen-tiation and treatment of traditional Chinese medicine[J]. J Hanan Med Coll, 2020, 26(11): 861-863, 867. DOI: 10.13210/j.cnki.jhmu.20200327.001.

    成扬, 倪赛赛, 陈建杰. 陈建杰教授运用中医辨证论治治疗肝癌术后经验探析[J]. 海南医学院学报, 2020, 26(11): 861-863, 867. DOI: 10.13210/j.cnki.jhmu.20200327.001.
    [19]
    SHI L, HAO JM, HANG JM, et al. Effect of Bailian Huapi decoction on vascular endothelial growth factor, liver function, and AFP-L3 expression in patients with primary liver cancer after[J]. Hainan Med J, 2021, 32(3): 278-281. DOI: 10.3969/j.issn.1003-6350.2021.03.002.

    石磊, 郝建梅, 杭嘉敏, 等. 白莲化癖汤对原发性肝癌TACE术后患者VEGF、肝功能及AFP-L3表达水平的影响[J]. 海南医学, 2021, 32(3): 278-281. DOI: 10.3969/j.issn.1003-6350.2021.03.002.
    [20]
    XU BW, ZHAO WZ, LI J, et al. A brief discussion of the method of lifting Yang and clearing fire in syndrome differentiation-based treatment of cancerous fever based on "There must be latent Yang where abdominal mass exists"[J]. Global Tradit Chin Med, 2021, 14(1): 132-134. DOI: 10.3969/j.issn.1674-1749.2021.01.035.

    许博文, 赵维哲, 李杰, 等. 基于"痞坚之处, 必有伏阳"浅论升阳散火法辨治癌性发热[J]. 环球中医药, 2021, 14(1): 132-134. DOI: 10.3969/j.issn.1674-1749.2021.01.035.
    [21]
    LI C, ZHOU XL, CHEN Q, et al. Clinical effect of Mahuang Shengma decoction in treatment of patients after transcatheter arterial chemoembolization for primary liver cancer[J]. Lishizhen Med Mater Med Res, 2018, 29(1): 114-116. DOI: 10.3969/j.issn.1008-0805.2018.01.037.

    李灿, 周晓玲, 陈峭, 等. 麻黄升麻汤治疗原发性肝癌TACE术后患者的疗效观察[J]. 时珍国医国药, 2018, 29(1): 114-116. DOI: 10.3969/j.issn.1008-0805.2018.01.037.
    [22]
    SUN TT, LI JT, LIU YG, et al. Professor Chang Zhanjie's experience in the treatment of abdominal distension due to liver cancer by treating obstruction with tonics[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30(3): 253-255. DOI: 10.3969/j.issn.1005-0264.2020.03.021.

    孙婷婷, 李京涛, 刘永刚, 等. 常占杰教授塞因塞用法论治肝癌性腹胀经验[J]. 中西医结合肝病杂志, 2020, 30(3): 253-255. DOI: 10.3969/j.issn.1005-0264.2020.03.021.
    [23]
    LI YY, WEI ZH, ZHONG QH, et al. Effect of Chinese medicine cinobufotalinon recurrence of hepatocellular carcinoma after TACE and expression of VEGF/TSGF in serum[J]. Liaoning J Tradit Chin Med, 2020, 47(1): 131-134. DOI: 10.13192/j.issn.1000-1719.2020.01.043.

    李岳勇, 韦忠恒, 钟秋红, 等. 中药华蟾素对肝细胞肝癌TACE术后肝内复发和血清VEGF/TSGF表达的影响[J]. 辽宁中医杂志, 2020, 47(1): 131-134. DOI: 10.13192/j.issn.1000-1719.2020.01.043.
    [24]
    ZHANG BR, HE SY, QIAO YL, et al. Prescription rules for the prescriptions containing scutellaria barbata and oldenlandia diffusa medicine based on traditional Chinese medicine inheritance system[J]. Lishizhen Med Mater Med Res, 2020, 31(9): 2291-2294. DOI: 10.3969/j.issn.1008-0805.2020.09.079.

    张伯瑞, 何世勇, 乔艳皊, 等. 基于中医传承辅助平台研究含半枝莲—白花蛇舌草药对方剂的组方规律[J]. 时珍国医国药, 2020, 31(9): 2291-2294. DOI: 10.3969/j.issn.1008-0805.2020.09.079.
    [25]
    ZHU HZ, SANG TQ, JI Y, et al. Study on target of treating tumors based on active constituents of Baihuasheshecao(Hedyotis diffusa) in XIaoai Jiedu decoction[J]. Chin Arch Tradit Chin Med, 2020, 38(5): 132-135, 276-277. DOI: 10.13193/j.issn.1673-7717.2020.05.031.

    朱恒舟, 桑天庆, 季漪, 等. 基于消癌解毒方中白花蛇舌草有效成分治疗肿瘤的靶点研究[J]. 中华中医药学刊, 2020, 38(5): 132-135, 276-277. DOI: 10.13193/j.issn.1673-7717.2020.05.031.
    [26]
    ZHANG RR, SHAO MY, FU Y, et al. Network Meta-analysis of oral Chinese patent medicine for adjuvant treatment of primary liver cancer[J]. China J Chin Mater Med, 2021, 46(9): 2333-2343. DOI: 10.19540/j.cnki.cjcmm.20200721.501.

    张容容, 邵明义, 符宇, 等. 口服中成药辅助治疗原发性肝癌的网状Meta分析[J]. 中国中药杂志, 2021, 46(9): 2333-2343. DOI: 10.19540/j.cnki.cjcmm.20200721.501.
    [27]
    DAI CM, JIN S, ZHANG JZ. Effect of Dahuang Zhechong Pills combined with TACE on VEGF, MMP-2, TGF-β1 and immune function of patients with primary liver cancer (blood stasis and collaterals blocking type)[J]. China J Chin Mater Med, 2021, 46(3): 722-729. DOI: 10.19540/j.cnki.cjcmm.20200716.501.

    戴朝明, 靳松, 张济周. 大黄蛰虫丸联合TACE术对原发性肝癌患者(瘀血阻络型)VEGF, MMP-2, TGF-β1及免疫功能的影响[J]. 中国中药杂志, 2021, 46(3): 722-729. DOI: 10.19540/j.cnki.cjcmm.20200716.501.
    [28]
    HU LJ, GUO TT, YE HY, et al. Discussion and application of Chinese medicine external treatment cascade quadruple therapy on cancer pain[J]. J Emerg Tradit Chin Med, 2021, 30(1): 105-108. DOI: 10.3969/j.issn.1004-745X.2021.01.029.

    胡陵静, 郭婷婷, 叶海英, 等. 中医外治四联梯级疗法治疗癌性疼痛的探讨与应用[J]. 中国中医急症, 2021, 30(1): 105-108. DOI: 10.3969/j.issn.1004-745X.2021.01.029.
    [29]
    LIU ZY, ZHANG HB, LUO Y, et al. Curative effect of YU Yun pulse-feeling-based acupuncture therapy for treatment of middle-late liver cancer[J]. J Guangzhou Univ Tradit Chin Med, 2018, 35(1): 66-69. DOI: 10.13359/j.cnki.gzxbtcm.2018.01.014.

    刘泽银, 张海波, 罗英, 等. 俞云切脉针灸治疗中晚期肝癌的疗效观察[J]. 广州中医药大学学报, 2018, 35(1): 66-69. DOI: 10.13359/j.cnki.gzxbtcm.2018.01.014.
    [30]
    YOU LN, WEI T, HUANG WK, et al. Clinical effect of acupuncture in treatment of hiccup in patients with primary liver cancer after transcatheter arterial chemoembolization: An analysis of 37 cases[J]. J Extern Ther Tradit Chin Med, 2017, 26(1): 33-35. DOI: 10.3969/j.issn.1006-978X.2017.01.018.

    由丽娜, 魏童, 黄伍奎, 等. 针灸治疗原发性肝癌患者经导管动脉化疗栓塞术后呃逆37例[J]. 中医外治杂志, 2017, 26(1): 33-35. DOI: 10.3969/j.issn.1006-978X.2017.01.018.
    [31]
    WANG J, SHI WH. Clinical effect of acupoint application combined with acupuncture in treatment of intractable hiccups after transcatheter arterial chemoembolization for liver cancer[J]. J Pract Tradit Chin Med, 2020, 36(12): 1641-1642. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYAO202012084.htm

    王瑾, 施伟华. 穴位敷贴结合针灸治疗肝癌经导管动脉栓塞术后顽固性呃逆临床观察[J]. 实用中医药杂志, 2020, 36(12): 1641-1642. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYAO202012084.htm
    [32]
    ZHANG YS, GUAN LW, DU W, et al. Therapeutic effect of pressing acupuncture combined with mosapride on gastrointestinal dysfunction after interventional chemoembolization of primary liver cancer[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30(5): 392-395. DOI: 10.3969/j.issn.1005-0264.2020.05.003.

    张永顺, 管莉文, 杜伟, 等. 揿针疗法联合莫沙必利治疗原发性肝癌化疗栓塞术后胃肠功能障碍研究[J]. 中西医结合肝病杂志, 2020, 30(5): 392-395. DOI: 10.3969/j.issn.1005-0264.2020.05.003.
    [33]
    SU F, SU ZY, YANG WJ, et al. Clinical effect of acupuncture combined with acupoint injection in treatment of pain in advanced liver cancer[J]. J World Latest Med Inf, 2019, 19(40): 191, 193. DOI: 10.19613/j.cnki.1671-3141.2019.40.124.

    宿峰, 宿兆颜, 杨文俊, 等. 针灸配合穴位注射治疗晚期肝癌疼痛的临床效果观察[J]. 世界最新医学信息文摘, 2019, 19(40): 191, 193. DOI: 10.19613/j.cnki.1671-3141.2019.40.124.
    [34]
    WANG KW, KUAI L, JIN SY, et al. External application's rule of treating cancerous pain based on traditional Chinese medicine inheritance support platform[J]. Chin J Basic Med Tradit Chin Med, 2020, 26(2): 254-257. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC202002033.htm

    王凯文, 蒯仂, 金燊懿, 等. 基于中医传承辅助平台的癌痛外敷方用药规律分析[J]. 中国中医基础医学杂志, 2020, 26(2): 254-257. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC202002033.htm
    [35]
    ZHANG X, MIN CY, SHI CF. Research on the effect of external application of traditional Chinese medicine on cancer pain in patients with liver cancer[J]. Chin Med Modern Distance Educ of China, 2020, 18(18): 76-78. DOI: 10.3969/j.issn.1672-2779.2020.18.030.

    张茜, 闵彩云, 施翠芬. 中药外敷对肝癌患者癌性疼痛的效果研究[J]. 中国中医药现代远程教育, 2020, 18(18): 76-78. DOI: 10.3969/j.issn.1672-2779.2020.18.030.
    [36]
    LIU JM, PENG XY. Clinical effect of external application of traditional Chinese medicine combined with moxibustion in treatment of malignant ascites: An analysis of 30 cases[J]. Hunan J Tradit Chin Med, 2018, 34(10): 111-112. DOI: 10.16808/j.cnki.issn.1003-7705.2018.10.053.

    刘健美, 彭小玉. 中药外敷联合艾灸干预癌性腹水30例效果观察[J]. 湖南中医杂志, 2018, 34(10): 111-112. DOI: 10.16808/j.cnki.issn.1003-7705.2018.10.053.
    [37]
    JIANG F, HONG LY, ZENG SC. Clinical study of navel therapy combined with Moxibustion in the treatment of malignant ascites[J]. Chin Foreign Med Res, 2020, 18(6): 133-135. DOI: 10.14033/j.cnki.cfmr.2020.06.056.

    江烽, 洪芦鱼, 曾水成. 中药脐疗联合艾灸治疗恶性腹腔积液的临床研究[J]. 中外医学研究, 2020, 18(6): 133-135. DOI: 10.14033/j.cnki.cfmr.2020.06.056.
    [38]
    CHU XL, SU YX, CHEN Z, et al. Application of the theory of "Caring the Healthy Part Firstly" in the prevention and treatment of cancer metastasis[J]. J Liaoning Univ Tradit Chin Med, 2020, 22(12): 75-78. DOI: 10.13194/j.issn.1673-842x.2020.12.017.

    褚雪镭, 苏毅馨, 陈峥, 等. "先安未受邪之地"理论在肿瘤转移防治中的应用[J]. 辽宁中医药大学学报, 2020, 22(12): 75-78. DOI: 10.13194/j.issn.1673-842x.2020.12.017.
    [39]
    LU YY, GAO ZH. Professor's Yin Changjian's experience in the treatment of high alpha-fetoprotein[J]. Chin J Integr Tradit West Med Liver Dis, 2013, 23(4): 237-238. DOI: 10.3969/j.issn.1005-0264.2013.04.016.

    鲁玉银, 高占华. 尹常健教授治疗高甲胎蛋白血症经验选介[J]. 中西医结合肝病杂志, 2013, 23(4): 237-238. DOI: 10.3969/j.issn.1005-0264.2013.04.016.
    [40]
    TANG ZY. Creation of Chinese new medicine in the era of Western medicine[M]. Shanghai: Shanghai Scientific & Technical Publishers, 2019: 5.

    汤钊猷. 西学中, 创中国新医学[M]. 上海: 上海科学技术出版社, 2019: 5.
    [41]
    WANG JB, YANG YF, WU Y, et al. A cohort study of Traditional Chinese Medicine (TCM) on primary liver cancer in the recurrence and metastasis after microwave ablation[J]. World Sci Technol Modern Tradit Chin Med, 2016, 18(10): 1640-1645. DOI: 10.11842/wst.2016.10.004.

    王建彬, 杨宇飞, 吴煜, 等. 中医药对原发性肝癌微波消融后复发转移影响的前瞻性队列研究[J]. 世界科学技术-中医药现代化, 2016, 18(10): 1640-1645. DOI: 10.11842/wst.2016.10.004.
    [42]
    ZHANG CA, GU YF, ZHANG YC, et al. Discussion on clinical thoughts for treating liver cancer recurrence and metastasis from phlegm[J]. J Oncol Chin Med, 2020, 2(1): 31-35. DOI: 10.19811/j.cnki.issn.2096-6628.2020.01.008.

    张慈安, 顾雨芳, 张映城, 等. 浅析从痰论治肝癌复发转移的临床思路[J]. 中医肿瘤学杂志, 2020, 2(1): 31-35. DOI: 10.19811/j.cnki.issn.2096-6628.2020.01.008.
    [43]
    GAO LY, WEI AL. Mechanism of action of blood-activating and stasis-resolving drugs on tumor metastasis and recurrence by regulating cytokines in hepatocellular carcinoma microenvironment: A preliminary study[J]. Global Tradit Chin Med, 2014, 7(2): 119-121. DOI: 10.3969/j.issn.1674-1749.2014.02.012.

    高连印, 韦艾凌. 活血化瘀药调控肝细胞癌微环境细胞因子影响肿瘤转移复发机制初探[J]. 环球中医药, 2014, 7(2): 119-121. DOI: 10.3969/j.issn.1674-1749.2014.02.012.
    [44]
    HUANG QF, WEI AL. Discussion on the treatment of metastasis and recurrence of hepatocellular carcinoma from the method of promoting blood circulation and removing blood stasis[J]. Lishizhen Med Mater Med Res, 2018, 29(8): 1944-1945. DOI: 10.3969/j.issn.1008-0805.2018.08.052.

    黄覃凤, 韦艾凌. 从活血化瘀法论治肝癌复发和转移的理论探讨[J]. 时珍国医国药, 2018, 29(8): 1944-1945. DOI: 10.3969/j.issn.1008-0805.2018.08.052.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (884) PDF downloads(92) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return